#begin document (nw/wsj/04/wsj_0468); part 000
nw/wsj/04/wsj_0468   0    0              G.D.   NNP       (TOP(S(NP*         -    -   -   -    (ORG*   (ARG0*        *        *   -
nw/wsj/04/wsj_0468   0    1            Searle   NNP                *         -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0468   0    2                 &    CC                *         -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0468   0    3               Co.   NNP                *)        -    -   -   -        *)       *)       *        *   -
nw/wsj/04/wsj_0468   0    4              said   VBD             (VP*        say  01   -   -        *      (V*)       *        *   -
nw/wsj/04/wsj_0468   0    5               the    DT      (SBAR(S(NP*         -    -   -   -    (ORG*   (ARG1*   (ARG0*        *   -
nw/wsj/04/wsj_0468   0    6              Food   NNP            (NML*         -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0468   0    7               and    CC                *         -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0468   0    8              Drug   NNP                *)        -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0468   0    9    Administration   NNP                *)        -    -   -   -        *)       *        *)       *   -
nw/wsj/04/wsj_0468   0   10          approved   VBD             (VP*    approve  01   -   -        *        *      (V*)       *   -
nw/wsj/04/wsj_0468   0   11               the    DT          (NP(NP*         -    -   -   -        *        *   (ARG1*        *   -
nw/wsj/04/wsj_0468   0   12              sale    NN                *)        -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0468   0   13                of    IN             (PP*         -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0468   0   14           Kerlone   NNP          (NP(NP*)        -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0468   0   15                 ,     ,                *         -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0468   0   16                 a    DT          (NP(NP*         -    -   -   -        *        *        *   (ARG1*   -
nw/wsj/04/wsj_0468   0   17      hypertension    NN                *         -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0468   0   18              drug    NN                *)        -    -   -   -        *        *        *        *)  -
nw/wsj/04/wsj_0468   0   19         developed   VBN             (VP*    develop  02   -   -        *        *        *      (V*)  -
nw/wsj/04/wsj_0468   0   20                by    IN             (PP*         -    -   -   -        *        *        *   (ARG0*   -
nw/wsj/04/wsj_0468   0   21                 a    DT          (NP(NP*         -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0468   0   22             joint    JJ                *         -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0468   0   23           venture    NN                *)        -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0468   0   24           between    IN             (PP*         -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0468   0   25            Searle   NNP          (NP(NP*)        -    -   -   -     (ORG)       *        *        *   -
nw/wsj/04/wsj_0468   0   26               and    CC                *         -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0468   0   27                 a    DT             (NP*         -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0468   0   28            French    JJ                *         -    -   -   -    (NORP)       *        *        *   -
nw/wsj/04/wsj_0468   0   29           concern    NN   *))))))))))))))        -    -   -   -        *        *)       *)       *)  -
nw/wsj/04/wsj_0468   0   30                 .     .               *))        -    -   -   -        *        *        *        *   -

nw/wsj/04/wsj_0468   0    0             Searle    NNP          (TOP(S(NP(NP*)      -    -   -   -     (ORG)  (ARG0*        *            *             *        *   -
nw/wsj/04/wsj_0468   0    1                  ,      ,                      *       -    -   -   -        *        *        *            *             *        *   -
nw/wsj/04/wsj_0468   0    2                  a     DT                (NP(NP*       -    -   -   -        *        *        *            *             *        *   -
nw/wsj/04/wsj_0468   0    3               unit     NN                      *)      -    -   -   -        *        *        *            *             *        *   -
nw/wsj/04/wsj_0468   0    4                 of     IN                   (PP*       -    -   -   -        *        *        *            *             *        *   -
nw/wsj/04/wsj_0468   0    5           Monsanto    NNP                   (NP*       -    -   -   -    (ORG*        *        *            *             *        *   -
nw/wsj/04/wsj_0468   0    6                Co.    NNP                    *)))      -    -   -   -        *)       *        *            *             *        *   -
nw/wsj/04/wsj_0468   0    7                  ,      ,                      *)      -    -   -   -        *        *)       *            *             *        *   -
nw/wsj/04/wsj_0468   0    8               said    VBD                   (VP*      say  01   -   -        *      (V*)       *            *             *        *   -
nw/wsj/04/wsj_0468   0    9                the     DT         (SBAR(S(NP(NP*       -    -   -   -        *   (ARG1*   (ARG1*            *             *        *   -
nw/wsj/04/wsj_0468   0   10                 ``     ``                      *       -    -   -   -        *        *        *            *             *        *   -
nw/wsj/04/wsj_0468   0   11               beta     NN                  (NML*       -    -   -   -        *        *        *            *             *        *   -
nw/wsj/04/wsj_0468   0   12                 -    HYPH                      *       -    -   -   -        *        *        *            *             *        *   -
nw/wsj/04/wsj_0468   0   13            blocker     NN                      *)      -    -   -   -        *        *        *            *             *        *   -
nw/wsj/04/wsj_0468   0   14                 ''     ''                      *       -    -   -   -        *        *        *            *             *        *   -
nw/wsj/04/wsj_0468   0   15               high     JJ                  (NML*       -    -   -   -        *        *        *            *             *        *   -
nw/wsj/04/wsj_0468   0   16                 -    HYPH                      *       -    -   -   -        *        *        *            *             *        *   -
nw/wsj/04/wsj_0468   0   17              blood     NN                      *       -    -   -   -        *        *        *            *             *        *   -
nw/wsj/04/wsj_0468   0   18                 -    HYPH                      *       -    -   -   -        *        *        *            *             *        *   -
nw/wsj/04/wsj_0468   0   19           pressure     NN                      *)      -    -   -   -        *        *        *            *             *        *   -
nw/wsj/04/wsj_0468   0   20               drug     NN                      *)      -    -   -   -        *        *        *            *             *        *   -
nw/wsj/04/wsj_0468   0   21            Kerlone    NNP                  (NP*))      -    -   -   -        *        *        *)           *             *        *   -
nw/wsj/04/wsj_0468   0   22                 is    VBZ                   (VP*       be  01   -   -        *        *      (V*)           *             *        *   -
nw/wsj/04/wsj_0468   0   23                the     DT                (NP(NP*       -    -   -   -        *        *   (ARG2*       (ARG0*             *        *   -
nw/wsj/04/wsj_0468   0   24              first     JJ                      *       -    -   -   -        *        *        *            *             *        *   -
nw/wsj/04/wsj_0468   0   25            product     NN                      *)      -    -   -   -        *        *        *            *)            *        *   -
nw/wsj/04/wsj_0468   0   26                 to     TO            (SBAR(S(VP*       -    -   -   -        *        *        *            *             *        *   -
nw/wsj/04/wsj_0468   0   27              reach     VB                   (VP*    reach  01   -   -        *        *        *          (V*)            *        *   -
nw/wsj/04/wsj_0468   0   28                the     DT                   (NP*       -    -   -   -        *        *        *       (ARG1*             *        *   -
nw/wsj/04/wsj_0468   0   29             market     NN                      *)      -    -   -   -        *        *        *            *)            *        *   -
nw/wsj/04/wsj_0468   0   30            through     IN                   (PP*       -    -   -   -        *        *        *   (ARGM-MNR*             *        *   -
nw/wsj/04/wsj_0468   0   31              Lorex    NNP                (NP(NP*       -    -   -   -    (ORG*        *        *            *             *        *   -
nw/wsj/04/wsj_0468   0   32    Pharmaceuticals    NNP                      *)      -    -   -   -        *)       *        *            *             *        *   -
nw/wsj/04/wsj_0468   0   33                  ,      ,                      *       -    -   -   -        *        *        *            *             *        *   -
nw/wsj/04/wsj_0468   0   34                the     DT                (NP(NP*       -    -   -   -        *        *        *            *        (ARG1*        *   -
nw/wsj/04/wsj_0468   0   35               U.S.    NNP                      *       -    -   -   -     (GPE)       *        *            *             *        *   -
nw/wsj/04/wsj_0468   0   36            company     NN                      *)      -    -   -   -        *        *        *            *             *)       *   -
nw/wsj/04/wsj_0468   0   37            jointly     RB              (VP(ADVP*)      -    -   -   -        *        *        *            *    (ARGM-MNR*)       *   -
nw/wsj/04/wsj_0468   0   38              owned    VBN                      *      own  01   -   -        *        *        *            *           (V*)       *   -
nw/wsj/04/wsj_0468   0   39                 by     IN                   (PP*       -    -   -   -        *        *        *            *        (ARG0*        *   -
nw/wsj/04/wsj_0468   0   40             Searle    NNP                (NP(NP*)      -    -   -   -     (ORG)       *        *            *             *        *   -
nw/wsj/04/wsj_0468   0   41                and     CC                      *       -    -   -   -        *        *        *            *             *        *   -
nw/wsj/04/wsj_0468   0   42         Synthelabo    NNP                (NP(NP*)      -    -   -   -     (ORG)       *        *            *             *        *   -
nw/wsj/04/wsj_0468   0   43                  ,      ,                      *       -    -   -   -        *        *        *            *             *        *   -
nw/wsj/04/wsj_0468   0   44                  a     DT                (NP(NP*       -    -   -   -        *        *        *            *             *   (ARG1*   -
nw/wsj/04/wsj_0468   0   45             French     JJ                      *       -    -   -   -    (NORP)       *        *            *             *        *   -
nw/wsj/04/wsj_0468   0   46     pharmaceutical     JJ                      *       -    -   -   -        *        *        *            *             *        *   -
nw/wsj/04/wsj_0468   0   47            concern     NN                      *)      -    -   -   -        *        *        *            *             *        *)  -
nw/wsj/04/wsj_0468   0   48              owned    VBN                   (VP*      own  01   -   -        *        *        *            *             *      (V*)  -
nw/wsj/04/wsj_0468   0   49                 by     IN                   (PP*       -    -   -   -        *        *        *            *             *   (ARG0*   -
nw/wsj/04/wsj_0468   0   50             France    NNP                (NP(NP*       -    -   -   -     (GPE)       *        *            *             *        *   -
nw/wsj/04/wsj_0468   0   51                 's    POS                      *)      -    -   -   -        *        *        *            *             *        *   -
nw/wsj/04/wsj_0468   0   52            L'Oreal    NNP                      *       -    -   -   -    (ORG*        *        *            *             *        *   -
nw/wsj/04/wsj_0468   0   53                S.A    NNP   *))))))))))))))))))))      -    -   -   -        *)       *)       *)           *)            *)       *)  -
nw/wsj/04/wsj_0468   0   54                  .      .                     *))      -    -   -   -        *        *        *            *             *        *   -

#end document
